Cabozantinib plus atezolizumab for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies a two-drug treatment (cabozantinib plus atezolizumab) for people with advanced or metastatic non-small cell lung cancer (NSCLC). It may help control the cancer and shrink tumors, especially for patients whose tumor tests show low PD-L1 and who fit the trial’s prior-treatment rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older and able to understand the study and sign consent (or have a legal representative do so)
- Have advanced or metastatic NSCLC confirmed by tumor testing, with PD-L1 less than 1% on a specific test (22C3)
- Be in good enough physical condition (ECOG 0–1) and have at least one measurable tumor spot on scans
- Be able to share tumor tissue for study testing (a new biopsy is optional but may be recommended if safe)
- Have not had the study drugs before, and be ready for washout timing from other treatments (no recent chemo/other cancer drugs, and no recent investigational drugs)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests whether combining atezolizumab and pirfenidone can help people with non-small cell lung cancer (NSCLC) after prior treatment. It is aimed at patients whose cancer has certain genetic markers ruled out and who can safely take study medicines and follow frequent visits.
This trial tests a combination of two drugs (tislelizumab and anlotinib) for people with advanced lung cancer whose first immunotherapy treatment stopped working. The goal is to see if this new combination can help when the first treatment stopped being effective.
This trial tests a new drug called BL-M14D1 combined with atezolizumab (an immunotherapy) against standard chemotherapy for extensive-stage small cell lung cancer, a serious type of lung cancer that has spread. The goal is to see if this combination helps patients live longer and control their cancer better.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This Phase 2 trial tests cabozantinib plus atezolizumab in people with metastatic prostate cancer that keeps growing despite hormone-blocking therapy and newer hormone drugs. It may help shrink tumors and control the disease, especially in advanced cases where options are limited.
This Phase 2 study tests whether combining cabozantinib with temozolomide can control advanced lung or gastrointestinal neuroendocrine tumors that have grown after prior treatments. It also closely monitors safety, including blood counts, organ function, and other side effects.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.